Serum lipid profile among non diabetic patients with chronic kidney disease attending tertiary care hospital in West Bengal, India
DOI:
https://doi.org/10.18203/2349-3933.ijam20184759Keywords:
Chronic kidney disease, Dyslipidemia, Glomerular filtration rate, Non diabetic, Renal functionAbstract
Background: Chronic kidney disease (CKD) is a major health deteriorating factor worldwide as well as in India. It encompasses various pathophysiological processes involving abnormal kidney function and thereby declination in glomerular filtration rate (GFR). CKD is known risk factor for dyslipidemia. Due to lack of studies of association between different lipid parameters and its association with severity of CKD in non-diabetic patients in Indian population, we designed a study aimed to describe the serum lipid profile in non-diabetic CKD patients.
Methods: This hospital based observational analytical was carried out in 60 subjects with CKD and non-diabetic. They were investigated for blood sugar parameters, lipid profile and renal function tests. Lipid profile was associated with different stages of CKD. Data was expressed as percentage and mean±SD.
Results: Mean BMI was found to be 21.6±2.7kg/m2. Most common symptom encountered was H/o edema in 98% subjects. Out of total sixty subjects’ maximum subjects were found to be in stage 4 (22 subjects, 36.7%). Significantly higher levels of serum creatinine (p <0.0001), and serum urea (p <0.0001) was observed in higher grade CKD stages in study subjects.
Conclusions: Total cholesterol (TC) and LDL were found to be significantly different amongst CKD stages having higher mean values in non-diabetic subjects. Serum TC, TG, LDL and VLDL were found to be significantly higher in subjects with advanced CKD (stage 3, stage 4). TC/HDL and LDL/HDL ratio were significantly higher in subjects with advanced CKD compared to initial stages of CKD in non-diabetic subjects.
References
Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general populations: new prospective study and systematic review. PLoS Med. 2007 Sep 4;4(9):e270.
Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J Am Soc Nephrol. 2002 Jan 1;13(suppl 1):S37-40.
Hallan SI, Coresh J, Astor BC, Åsberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk. J Am Soc Nephrol. 2006 Aug 1;17(8):2275-84.
Dor A, Pauly MV, Eichleay MA. Held PJ. End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). Int J Health Care Finance Econ. 2007;7:73-111.
Verma PP. Prevalence of chronic kidney disease in India - Where are we heading?. Indian J Nephrol. 2015;25(3):133-5.
Locatelli F, Pozzoni P, Del LV. Epidemiology of chronic kidney disease in Italy: possible therapeutical approaches. J Nephrol. 2003;16(1):1-10.
Mathenge RN, Mcligego SO, Mutua AK, Otieno LS. The spectrum of echocardiographic finding in chronic renal failure. East Africa Med J. 2003;70(3):97-103.
Moronkola OA, Ojediran MM, Amosu A. Menstrual disorder in chronic renal failure patients attending renal clinics in Ibadan, Nigeria. African Health Sci. 2006;6(3):155-60.
Riepponen P, Maniemit J, Flanwlya AC. Immunoturbidimetric determination of apolipoprotein A1 and B in serum. JJ Clin Lab Invest. 1987;47:739-44.
Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, et al. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dialysis Transplantation. 1997 Sep 1;12(9):1908-15.
Castelló IB. Hyperlipidemia: a risk factor for chronic allograft dysfunction. Kidney Int. 2002 May 1;61:S73-7.
Brosnahan G, Fraer M. Chronic kidney disease: whom to screen and how to treat, part 1: definition, epidemiology, and laboratory testing. Southern medical journal. 2010 Feb;103(2):140-6.
Ravichandran R. Hyperlipidemia in patients with chronic renal failure. J Postgrad Med. 1983;29(4):212-17.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan 1;3(1):1-50.
Magar LRS, Mohammad AM, Anil SS. A study of lipid profile in chronic renal failure patients undergoing haemodialysis. J Dental Med Sci (IOSR-JDMS). 2016;15(6):1-3.
Gelber RP, Kurth T, Kausz AT, Manson JE, Buring JE, Levey AS, et al. Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis. 2005 Nov 1;46(5):871-80.
Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004 Feb 18;291(7):844-50.
Chen SC, Hung CC, Kuo MC, Lee JJ, Chiu YW, Chang J, et al. Association of dyslipidemia with renal outcomes in chronic kidney disease. PLoS One. 2013 8(2):e55643.
Ganta V, Yalamanchi RP, Mahanta KC, Sahu B, Raghvendar K, Anusha G, et al. A study of lipid profile in non-diabetic chronic kidney disease. Int J Advances Med. 2016 Dec 24;3(4):965-70.
Mohanraj P, Ambazhagan G, Kallaivali S. Evaluation of lipid profile in non - diabetic chronic kidney disease stage 3 and 4. J Evidence Based Med Healthcare. 2014;1(6):338-46.
Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int. 2005 Dec 1;68:S87-93.
Weiner DE, Sarnak MJ. Managing dyslipidemia in chronic kidney disease. J Gen Intern Med. 2004;19:1045-52.
Shurraw S, Tonelli M. Statins for treatment of dyslipidemia in chronic kidney disease. Peritoneal Dialysis Int. 2006 Sep 1;26(5):523-39.
Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011;5:41-8.
Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007 Mar 14;18:1246-61.
Piecha G, Adamczak M, Ritz E. Dyslipidemia in chronic kidney disease. Pol Arch Med Wewn. 2009 Jul-Aug;119(7-8):487-92.
